Henry Ji

479 total citations
21 papers, 239 citations indexed

About

Henry Ji is a scholar working on Oncology, Infectious Diseases and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Henry Ji has authored 21 papers receiving a total of 239 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Infectious Diseases and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Henry Ji's work include SARS-CoV-2 and COVID-19 Research (7 papers), CAR-T cell therapy research (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Henry Ji is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (7 papers), CAR-T cell therapy research (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Henry Ji collaborates with scholars based in United States and Sweden. Henry Ji's co-authors include Namir Shaabani, Roshni Ramachandran, Robert D. Allen, Wenshe Ray Liu, Yuying Ma, Erol C. Vatansever, R. Xinyu, Zhi Geng, Yugendar R. Alugubelli and Kai S. Yang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cancer Research.

In The Last Decade

Henry Ji

21 papers receiving 238 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Henry Ji United States 9 101 75 68 49 36 21 239
Erli You China 8 79 0.8× 155 2.1× 50 0.7× 17 0.3× 38 1.1× 11 329
Christophe Buyck Belgium 8 136 1.3× 157 2.1× 81 1.2× 25 0.5× 29 0.8× 15 356
Fabao Zhao China 12 155 1.5× 130 1.7× 26 0.4× 25 0.5× 54 1.5× 49 396
Zheng Yao Low Malaysia 8 159 1.6× 80 1.1× 56 0.8× 24 0.5× 39 1.1× 12 289
Xiaoqi Chen China 14 43 0.4× 114 1.5× 14 0.2× 53 1.1× 75 2.1× 38 342
Bartłomiej Pawlik Poland 6 125 1.2× 122 1.6× 107 1.6× 37 0.8× 41 1.1× 14 342
Line A. Ryberg Denmark 7 179 1.8× 106 1.4× 67 1.0× 15 0.3× 15 0.4× 10 287
Mohamed Mahdi Hungary 7 124 1.2× 96 1.3× 76 1.1× 10 0.2× 23 0.6× 26 264
Almagul Seitova Canada 5 104 1.0× 59 0.8× 40 0.6× 30 0.6× 28 0.8× 8 198
Cecylia S. Lupala China 12 162 1.6× 222 3.0× 52 0.8× 15 0.3× 17 0.5× 21 382

Countries citing papers authored by Henry Ji

Since Specialization
Citations

This map shows the geographic impact of Henry Ji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry Ji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry Ji more than expected).

Fields of papers citing papers by Henry Ji

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henry Ji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry Ji. The network helps show where Henry Ji may publish in the future.

Co-authorship network of co-authors of Henry Ji

This figure shows the co-authorship network connecting the top 25 collaborators of Henry Ji. A scholar is included among the top collaborators of Henry Ji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry Ji. Henry Ji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Springer, Aaron D., et al.. (2024). Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma. Cancer Research Communications. 4(10). 2660–2672. 2 indexed citations
2.
3.
Lim, Reyna K. V., Matthew D. Buschman, Alisher Khasanov, et al.. (2023). Discovery of novel cMET-targeting antibody Fab drug conjugates as potential treatment for solid tumors with highly expressed cMET. Expert Opinion on Biological Therapy. 23(11). 1137–1149. 1 indexed citations
4.
Geng, Zhi, Namir Shaabani, Kai S. Yang, et al.. (2023). A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease. Journal of Medicinal Chemistry. 66(16). 11040–11055. 14 indexed citations
5.
Alugubelli, Yugendar R., Zhi Geng, Kai S. Yang, et al.. (2022). A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals. European Journal of Medicinal Chemistry. 240. 114596–114596. 33 indexed citations
6.
Ma, Yuying, Kai S. Yang, Zhi Geng, et al.. (2022). A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals. European Journal of Medicinal Chemistry. 240. 114570–114570. 28 indexed citations
7.
Thaker, Youg Raj, Alok R. Singh, Barbara Swanson, et al.. (2022). A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells. Frontiers in Oncology. 12. 884196–884196. 10 indexed citations
8.
Cao, Wenyue, Zhi Geng, Namir Shaabani, et al.. (2022). Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay. ACS Central Science. 8(2). 192–204. 38 indexed citations
9.
Chen, Runqiang, Namir Shaabani, Hua Wang, et al.. (2022). Delivering an mRNA vaccine using a lymphatic drug delivery device improves humoral and cellular immunity against SARS-CoV-2. Journal of Molecular Cell Biology. 14(6). 3 indexed citations
10.
Shaabani, Namir, Lisa M. Eubanks, Junki Maruyama, et al.. (2021). Salicylanilides Reduce SARS-CoV-2 Replication and Suppress Induction of Inflammatory Cytokines in a Rodent Model. ACS Infectious Diseases. 7(8). 2229–2237. 13 indexed citations
11.
Ji, Henry, Ying Yan, Beibei Ding, et al.. (2020). Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus. SHILAP Revista de lepidopterología. 5. 100026–100026. 12 indexed citations
12.
Ramachandran, Roshni, et al.. (2020). The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resiniferatoxin to improve prognosis: A review. SHILAP Revista de lepidopterología. 5. 100033–100033. 33 indexed citations
13.
Li, Lingna, Andrew M. Hau, Tong Zhu, et al.. (2020). Abstract LB-227: Preclinical development and characterization of STI-6129, an anti-CD38 antibody-drug conjugate, as a new therapeutic agent for multiple myeloma. Cancer Research. 80(16_Supplement). LB–227. 6 indexed citations
14.
Li, Lingna, Tong Zhu, Alisher Khasanov, et al.. (2019). Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies. Blood. 134(Supplement_1). 5621–5621. 6 indexed citations
15.
Somanchi, Srinivas S., Xuan Guo, Rohit Mathur, et al.. (2019). Development of CD38 CAR Engineered Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (PNK-CAR38) As Allogeneic Cancer Immunotherapy. Blood. 134(Supplement_1). 2070–2070. 5 indexed citations
16.
Ng, Mah Lee, Weifang Ling, Gunnar F. Kaufmann, et al.. (2019). Preclinical Evaluation of Human Placental-Derived Allogeneic CD19 CAR-T Cells Against B Cell Malignancies. Blood. 134(Supplement_1). 3222–3222. 5 indexed citations
17.
Zhang, Nan, Yanliang Zhang, Xia Cao, et al.. (2019). Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure. Blood. 134(Supplement_1). 1942–1942. 2 indexed citations
18.
Zhang, Yanliang, Nan Zhang, Robert Knight, et al.. (2019). Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure. Blood. 134(Supplement_1). 4444–4444. 2 indexed citations
19.
He, Xiao Yan, Yanliang Zhang, Yan Li, et al.. (2019). Preclinical Characterization of an ANTI-CD38/CD3 T CELL-Redirecting Bispecific Antibody. Blood. 134(Supplement_1). 4463–4463. 3 indexed citations
20.
Zhang, Yanliang, et al.. (2011). Recombinant antibody libraries and selection technologies. New Biotechnology. 28(5). 448–452. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erli You Breakdown of academic impact, for papers by Christophe Buyck Breakdown of academic impact, for papers by Fabao Zhao Breakdown of academic impact, for papers by Zheng Yao Low Breakdown of academic impact, for papers by Xiaoqi Chen Breakdown of academic impact, for papers by Bartłomiej Pawlik Breakdown of academic impact, for papers by Line A. Ryberg Breakdown of academic impact, for papers by Mohamed Mahdi Breakdown of academic impact, for papers by Almagul Seitova Breakdown of academic impact, for papers by Cecylia S. Lupala
Rankless by CCL
2026